Texas Roadhouse earnings missed by $0.05, revenue topped estimates
Investing.com - Stifel has raised its price target on Johnson & Johnson (NYSE:JNJ) to $165.00 from $155.00 while maintaining a Hold rating on the healthcare giant’s stock.
The price target increase follows JNJ’s updated guidance, which now projects adjusted operational revenue growth of approximately 3.5%, up from the previous estimate of 2.5% at the midpoint. This growth excludes foreign exchange impacts, acquisitions, and divestitures. According to InvestingPro data, JNJ maintains a "GOOD" overall financial health score, with particularly strong marks in profitability metrics.
JNJ has also revised its full-year earnings per share guidance upward to a range of $10.80-$10.90, compared to the previous guidance of $10.50-$10.70. The company attributes this improvement to currency effects, stronger top-line performance, and a reduced expected impact from tariffs.
The healthcare company now anticipates a $200 million tariff impact in 2025, down from its previous estimate of $400 million. JNJ’s forward commentary has emphasized top-line growth acceleration, while noting that uncertainties about tariffs and other factors are affecting visibility on operative leverage.
Multiple new product launches are driving the company’s confidence in its positive outlook, according to JNJ’s recent statements. Stifel’s new price target is based on a sum-of-the-parts analysis of the company’s business segments.
In other recent news, Johnson & Johnson has been the subject of several notable developments. Wolfe Research reiterated its Outperform rating on the company, projecting second-quarter 2025 revenues of $22.8 billion, aligning closely with consensus estimates. The research firm also forecasts full-year revenues of $91.9 billion, slightly above the consensus. Goldman Sachs maintained its Conviction Buy rating, noting that Johnson & Johnson’s Innovative Medicine segment, which constitutes a significant portion of its profit, is expected to perform strongly. Johnson & Johnson submitted a supplemental New Drug Application for CAPLYTA to the FDA for schizophrenia relapse prevention, backed by Phase 3 trial data. Additionally, the company’s IMAAVY, an FcRn blocker, demonstrated sustained disease control in a study for generalized myasthenia gravis. In oncology, Johnson & Johnson’s experimental dual-targeting CAR T-cell therapy showed promising results in patients with relapsed or refractory large B-cell lymphoma, with high response rates and a favorable safety profile. These developments are part of Johnson & Johnson’s ongoing efforts to strengthen its product portfolio and address investor concerns.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.